Skip to Content

    Late in 2005 the Food and Drug Administration approved ­Celgene’s Revlimid. The drug brought in $321 million in sales its first full year on the market. A decade later it collected a cool $6.97 billion (more than 60% of the biotech’s 2016 revenues), and sales are expected to cross the $8 billion mark this year. Celgene has ridden Revlimid’s success and approvals for various diseases to a 270% gain in market value in 10 years. Now analysts are bullish on the com­pany’s experimental treatments for multiple sclerosis, ulcerative colitis, and Crohn’s disease.

    Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

    Company Information

    Overall Score1.7
    Health Care
    Mark J. Alles
    HQ Location
    Summit, N.J.
    Revenues ($M) (Past 12 Months)$12,191
    Profits ($M) (Past 12 Months)$2,602
    Market Value as of Oct. 9, 2017 ($M)$108,958